Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Darr

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Clinical Genitourinary Cancer|April 15, 2025
Impact of Extended Versus Limited Lymph Node Dissection on Surgical Outcome, Recurrence Patterns and Survival After Radical CystectomyMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
Urologia Internationalis|December 16, 2024
Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial Carcinoma of the Bladder: 20 Years of Experience in a Tertiary CenterMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
European Urology Open Science|November 17, 2025
Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysisMohammed Altenni, Péter Fehérvári, Jakub Hoferica, et al.
Cancer Reports (Hoboken, N.J.)|December 28, 2024
Short-Term Urinary Incontinence After Radical Prostatectomy Is Still Based on Patients' Age, Nerve-Sparing Approach, and Surgical-Experience, Despite the Higher-Use of Robotic Surgery in 2022 Compared to 2016 Real-World Results of a Large Rehabilitation Center in GermanyLukas Püllen, Max Naumann, Ulrich Krafft, et al.
Theranostics|October 3, 2025
Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA TherapyAnalena Handke, Leonor Lopes, Claudia Kesch, et al.
BJU International|January 13, 2025
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancerCsilla Olah, Lara Sichward, Boris Hadaschik, et al.
Clinical Genitourinary Cancer|June 17, 2026
Assessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsLars Drüke, Jessica Schmitz, Manuel M Vicente, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 2, 2020
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using <sup>68</sup>Ga-PSMA-11Christopher Darr, U Krafft, W P Fendler, et al.
Urologia Internationalis|June 28, 2018
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate CancerChristopher Darr, Ulrich Krafft, Boris Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 6, 2021
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranosticsClaudia Kesch, Leubet Yirga, Katharina Dendl, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Clinical Genitourinary Cancer|April 15, 2025
Impact of Extended Versus Limited Lymph Node Dissection on Surgical Outcome, Recurrence Patterns and Survival After Radical CystectomyMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
Urologia Internationalis|December 16, 2024
Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial Carcinoma of the Bladder: 20 Years of Experience in a Tertiary CenterMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
European Urology Open Science|November 17, 2025
Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysisMohammed Altenni, Péter Fehérvári, Jakub Hoferica, et al.
Cancer Reports (Hoboken, N.J.)|December 28, 2024
Short-Term Urinary Incontinence After Radical Prostatectomy Is Still Based on Patients' Age, Nerve-Sparing Approach, and Surgical-Experience, Despite the Higher-Use of Robotic Surgery in 2022 Compared to 2016 Real-World Results of a Large Rehabilitation Center in GermanyLukas Püllen, Max Naumann, Ulrich Krafft, et al.
Theranostics|October 3, 2025
Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA TherapyAnalena Handke, Leonor Lopes, Claudia Kesch, et al.
BJU International|January 13, 2025
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancerCsilla Olah, Lara Sichward, Boris Hadaschik, et al.
Clinical Genitourinary Cancer|June 17, 2026
Assessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsLars Drüke, Jessica Schmitz, Manuel M Vicente, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 2, 2020
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using <sup>68</sup>Ga-PSMA-11Christopher Darr, U Krafft, W P Fendler, et al.
Urologia Internationalis|June 28, 2018
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate CancerChristopher Darr, Ulrich Krafft, Boris Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 6, 2021
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranosticsClaudia Kesch, Leubet Yirga, Katharina Dendl, et al.
Pageof 7